Limits...
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B.

Cui G, Xu X, Diao H - Sci Rep (2015)

Bottom Line: Tenofovir disoproxil fumarate (TDF) monotherapy has proven superior antiviral efficacy in chronic hepatitis B (CHB) patients; however, whether the combination of TDF and emtricitabine (FTC) exerts a significant advantage remains controversial.A meta-analysis was performed to comprehensively compare the therapeutic effects of FTC/TDF combination with TDF alone in CHB patients.In patients with nucleos(t)ide treatment history, no differences were noted between the two treatment groups after 12, 24, 48 and 96 weeks.

View Article: PubMed Central - PubMed

Affiliation: 1] State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

ABSTRACT
Tenofovir disoproxil fumarate (TDF) monotherapy has proven superior antiviral efficacy in chronic hepatitis B (CHB) patients; however, whether the combination of TDF and emtricitabine (FTC) exerts a significant advantage remains controversial. A meta-analysis was performed to comprehensively compare the therapeutic effects of FTC/TDF combination with TDF alone in CHB patients. Five studies involving 614 patients were identified, and subgroup analysis was performed based on the nucleos(t)ide treatment history. Our results revealed that in patients with nucleos(t)ide-naïve treatment, there were no significant differences between the treatment groups with TDF alone and FTC/TDF combination after 12 and 24 weeks; however, the FTC/TDF combination showed better viral suppression efficacy versus TDF alone after 48 (OR = 2.16, 95% CI = 1.06-4.41, P = 0.03), 96 (OR = 2.76, 95% CI = 1.29-5.92, P = 0.009) and 192 weeks (OR = 2.60, 95% CI = 1.21-5.56, P = 0.01). In patients with nucleos(t)ide treatment history, no differences were noted between the two treatment groups after 12, 24, 48 and 96 weeks. Our results indicated that FTC/TDF combination showed better viral suppression efficacy versus TDF alone in CHB patients with nucleos(t)ide-naïve treatment, while both treatments provided similar viral suppression efficacy in CHB patients with nucleos(t)ide treatment history.

No MeSH data available.


Related in: MedlinePlus

Forest plot displaying the secondary outcomes of safety assessment for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.Forest plot showed the comparison of (a) overall AE, (b) drug-related AE, (c) SAE and (d) drug-related SAE for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499796&req=5

f4: Forest plot displaying the secondary outcomes of safety assessment for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.Forest plot showed the comparison of (a) overall AE, (b) drug-related AE, (c) SAE and (d) drug-related SAE for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.

Mentions: The total analysis for comparison of overall AE between the treatment groups with TDF alone and FTC/TDF combination showed no obvious difference with regard to overall AE (Fig. 4a, OR = 0.58, 95% CI = 0.17–1.95, P = 0.38, I2 = 77%, the random effect model). Furthermore, there was no significant difference between the two treatment groups with regard to drug-related AE (Fig. 4b, OR = 1.16, 95% CI = 0.65–2.08, P = 0.62, I2 = 0%).


Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B.

Cui G, Xu X, Diao H - Sci Rep (2015)

Forest plot displaying the secondary outcomes of safety assessment for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.Forest plot showed the comparison of (a) overall AE, (b) drug-related AE, (c) SAE and (d) drug-related SAE for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499796&req=5

f4: Forest plot displaying the secondary outcomes of safety assessment for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.Forest plot showed the comparison of (a) overall AE, (b) drug-related AE, (c) SAE and (d) drug-related SAE for CHB patients after treatments with TDF alone and FTC/TDF combination, respectively.
Mentions: The total analysis for comparison of overall AE between the treatment groups with TDF alone and FTC/TDF combination showed no obvious difference with regard to overall AE (Fig. 4a, OR = 0.58, 95% CI = 0.17–1.95, P = 0.38, I2 = 77%, the random effect model). Furthermore, there was no significant difference between the two treatment groups with regard to drug-related AE (Fig. 4b, OR = 1.16, 95% CI = 0.65–2.08, P = 0.62, I2 = 0%).

Bottom Line: Tenofovir disoproxil fumarate (TDF) monotherapy has proven superior antiviral efficacy in chronic hepatitis B (CHB) patients; however, whether the combination of TDF and emtricitabine (FTC) exerts a significant advantage remains controversial.A meta-analysis was performed to comprehensively compare the therapeutic effects of FTC/TDF combination with TDF alone in CHB patients.In patients with nucleos(t)ide treatment history, no differences were noted between the two treatment groups after 12, 24, 48 and 96 weeks.

View Article: PubMed Central - PubMed

Affiliation: 1] State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

ABSTRACT
Tenofovir disoproxil fumarate (TDF) monotherapy has proven superior antiviral efficacy in chronic hepatitis B (CHB) patients; however, whether the combination of TDF and emtricitabine (FTC) exerts a significant advantage remains controversial. A meta-analysis was performed to comprehensively compare the therapeutic effects of FTC/TDF combination with TDF alone in CHB patients. Five studies involving 614 patients were identified, and subgroup analysis was performed based on the nucleos(t)ide treatment history. Our results revealed that in patients with nucleos(t)ide-naïve treatment, there were no significant differences between the treatment groups with TDF alone and FTC/TDF combination after 12 and 24 weeks; however, the FTC/TDF combination showed better viral suppression efficacy versus TDF alone after 48 (OR = 2.16, 95% CI = 1.06-4.41, P = 0.03), 96 (OR = 2.76, 95% CI = 1.29-5.92, P = 0.009) and 192 weeks (OR = 2.60, 95% CI = 1.21-5.56, P = 0.01). In patients with nucleos(t)ide treatment history, no differences were noted between the two treatment groups after 12, 24, 48 and 96 weeks. Our results indicated that FTC/TDF combination showed better viral suppression efficacy versus TDF alone in CHB patients with nucleos(t)ide-naïve treatment, while both treatments provided similar viral suppression efficacy in CHB patients with nucleos(t)ide treatment history.

No MeSH data available.


Related in: MedlinePlus